134 related articles for article (PubMed ID: 161840)
1. [Molybdocene dichloride as an antitumor agent (author's transl)].
Köpf-Maier P; Leitner M; Voigtländer R; Köpf H
Z Naturforsch C Biosci; 1979 Dec; 34(12):1174-6. PubMed ID: 161840
[TBL] [Abstract][Full Text] [Related]
2. [Tumor inhibition by metallocenes: effect of titanocene, zirconocene, and hafnocene dichlorides on Ehrlich ascites tumor in mice (author's transl)].
Köpf-Maier P; Hesse B; Köpf H
J Cancer Res Clin Oncol; 1980 Jan; 96(1):43-51. PubMed ID: 7188941
[TBL] [Abstract][Full Text] [Related]
3. In vitro cell growth inhibition by metallocene dichlorides.
Köpf-Maier P; Wagner W; Köpf H
Cancer Chemother Pharmacol; 1981; 5(4):237-41. PubMed ID: 7261252
[TBL] [Abstract][Full Text] [Related]
4. Organometallic anticancer agents: cellular uptake and cytotoxicity studies on thiol derivatives of the antitumor agent molybdocene dichloride.
Waern JB; Dillon CT; Harding MM
J Med Chem; 2005 Mar; 48(6):2093-9. PubMed ID: 15771451
[TBL] [Abstract][Full Text] [Related]
5. Cytokinetic behavior of Ehrlich ascites tumor after in vivo treatment with cis-diamminedichloroplatinum(II) and metallocene dichlorides.
Köpf-Maier P; Wagner W; Liss E
J Cancer Res Clin Oncol; 1981; 102(1):21-30. PubMed ID: 7199526
[TBL] [Abstract][Full Text] [Related]
6. Immunologic response to the treatment of Ehrlich ascites tumor with titanocene dichloride.
Köpf-Maier P; Hesse A
J Cancer Res Clin Oncol; 1984; 108(2):254-5. PubMed ID: 6540782
[TBL] [Abstract][Full Text] [Related]
7. Titanocene dichloride--the first metallocene with cancerostatic activity.
Köpf H; Köpf-Maier P
Angew Chem Int Ed Engl; 1979 Jun; 18(6):477-8. PubMed ID: 111586
[No Abstract] [Full Text] [Related]
8. Antitumor properties of organometallic metallocene complexes of tin and germanium.
Köpf-Maier P; Janiak C; Schumann H
J Cancer Res Clin Oncol; 1988; 114(5):502-6. PubMed ID: 3182909
[TBL] [Abstract][Full Text] [Related]
9. [Effects of various antitumor agents on intracerebrally inoculated Ehrlich ascites carcinoma in mice (author's transl)].
Zhou JX; He GH; Tao LX; Xu B
Zhongguo Yao Li Xue Bao; 1981 Dec; 2(4):256-61. PubMed ID: 6462026
[No Abstract] [Full Text] [Related]
10. Tumor inhibition by metallocenes: activity against leukemias and detection of the systemic effect.
Köpf-Maier P; Wagner W; Hesse B; Köpf H
Eur J Cancer (1965); 1981 Jun; 17(6):665-9. PubMed ID: 7308264
[No Abstract] [Full Text] [Related]
11. The first organoantimony(III) compounds possessing antitumor properties: diphenylantimony(III) derivatives of dithiophosphorus ligands.
Silvestru C; Socaciu C; Bara A; Haiduc I
Anticancer Res; 1990; 10(3):803-4. PubMed ID: 2369094
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of ionic niobocene and molybdenocene complexes in high oxidation states.
Köpf-Maier P; Klapötke T
J Cancer Res Clin Oncol; 1992; 118(3):216-21. PubMed ID: 1548287
[TBL] [Abstract][Full Text] [Related]
13. Spermicidal activity of metallocene complexes containing vanadium(IV) in humans.
D'Cruz OJ; Ghosh P; Uckun FM
Biol Reprod; 1998 Jun; 58(6):1515-26. PubMed ID: 9623614
[TBL] [Abstract][Full Text] [Related]
14. Induction of cell arrest at G1/S and in G2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro.
Köpf-Maier P; Wagner W; Liss E
J Cancer Res Clin Oncol; 1983; 106(1):44-52. PubMed ID: 6684118
[TBL] [Abstract][Full Text] [Related]
15. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
16. Antitumor organometallics. I. Activity of some diphenyltin(IV) and diphenylantimony(III) derivatives on in vitro and in vivo Ehrlich ascites tumor.
Bara A; Socaciu C; Silvestru C; Haiduc I
Anticancer Res; 1991; 11(4):1651-5. PubMed ID: 1836124
[TBL] [Abstract][Full Text] [Related]
17. Antitumor metallocenes: new developments and toxicologic features.
Köpf-Maier P; Köpf H
Anticancer Res; 1986; 6(2):227-33. PubMed ID: 3707060
[TBL] [Abstract][Full Text] [Related]
18. Ionic rhenocene derivatives with antitumor activity.
Köpf-Maier P; Klapötke T
Cancer Chemother Pharmacol; 1992; 29(5):361-6. PubMed ID: 1551174
[TBL] [Abstract][Full Text] [Related]
19. Tumor inhibition by titanocene dichloride: first clues to the mechanism of action.
Köpf-Maier P; Köpf H
Naturwissenschaften; 1980 Aug; 67(8):415-6. PubMed ID: 7191057
[No Abstract] [Full Text] [Related]
20. Coordination chemistry of the antitumor metallocene molybdocene dichloride with biological ligands.
Waern JB; Harding MM
Inorg Chem; 2004 Jan; 43(1):206-13. PubMed ID: 14704069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
